Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke
NCT02956200 · Second Affiliated Hospital, Zhejiang University, School of Medicine · PHASE2 · withdrawn · last registry update 2021-07-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Second Affiliated Hospital, Zhejiang University, School of Medicine |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against S1PR5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-07-22Phase 3 first posted: Bristol-Myers Squibb, Ozanimod (NCT05470985)
- 2022-03-24Results posted on the registry: Arena Pharmaceuticals, APD334 (NCT03155932)
- 2022-03-24Also stopped (terminated): Arena Pharmaceuticals, APD334 (NCT03155932)
- 2021-11-26Results posted on the registry: Arena Pharmaceuticals, Etrasimod + Placebo (NCT02536404)
- 2021-11-17Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab + Fingolimod (NCT05123703)
- 2021-10-13Phase 3 first posted: Bristol-Myers Squibb, Ozanimod (NCT05076175)
- 2021-09-01Results posted on the registry: Celgene, RPC1063 + Placebo (NCT02435992)
- 2021-08-31Phase 3 first posted: Celgene, Tetanus, diphtheria, and acellular pertussis vaccine + Pneumococcal polysaccharide vaccine (NCT05028634)
- 2021-07-29Also stopped (terminated): Charite University, Berlin, Germany, Verum arm receiving Gilenya® + Active Comparator receiving Extavia® (NCT01647880)
- 2021-06-15Phase 3 first posted: Novartis Pharmaceuticals, Fingolimod + Ofatumumab (NCT04926818)
- 2021-06-11Results posted on the registry: Arena Pharmaceuticals, APD334 (NCT03072953)
- 2021-06-11Also stopped (terminated): Arena Pharmaceuticals, APD334 (NCT03072953)
- 2021-04-05Results posted on the registry: Arena Pharmaceuticals, Etrasimod + Placebo (NCT02447302)
- 2021-02-11Results posted on the registry: Celgene, Ozanimod + Ozanimod placebo (NCT02047734)
- 2021-02-11Results posted on the registry: Celgene, Ozanimod + Placebo (NCT01628393)
- 2021-02-10Results posted on the registry: Novartis Pharmaceuticals, Fingolimod (NCT02232061)
- 2021-01-13Phase 3 first posted: Pfizer, Etrasimod + Placebo (NCT04706793)
- 2020-12-31Results posted on the registry: Arena Pharmaceuticals, APD334 (NCT03139032)
- 2020-12-31Also stopped (terminated): Arena Pharmaceuticals, APD334 (NCT03139032)
- 2020-11-25Results posted on the registry: Celgene, Ozanimod + Interferon beta-1a (NCT02294058)
- 2020-11-13Also stopped (withdrawn): First Affiliated Hospital of Fujian Medical University, Fingolimod 0.5 mg (NCT04280588)
- 2020-10-14Results posted on the registry: Celgene, Ozanimod + Placebo (NCT01647516)
- 2020-10-08Results posted on the registry: Celgene, RPC1063 (NCT02531113)
- 2020-08-12Results posted on the registry: Northwestern University, Standard treatment with a conventional drug (NCT00273364)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision